Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06089421
Other study ID # HSR230209
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 20, 2023
Est. completion date March 15, 2025

Study information

Verified date October 2023
Source University of Virginia
Contact Graham Fowler
Phone (434) 323-1749
Email NVG4WM@uvahealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing? Participants will: - have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot - answer questions about their cancer genetic knowledge and how they are doing - provide a saliva sample for genetic testing to test for cancer gene mutations - have their genetic testing results provided to them. - have the option to share their genetic testing results with family members Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.


Description:

High risk patients will be randomized to standard of care telegenetics with a UVA Genetic Counselor (GC) for pre-test counseling or to the novel interventional arm of pre-test counseling via Genetic Information Assistant (GIA). Participants in the study will receive their link for a telegenetics appointment or GIA link based on randomization and patients will complete pre-test genetic counseling via their assigned treatment arm. Participants will not be masked to their trial arm assignment. In the telegenetics arm, patients will be offered a video visit scheduled through Epic zoom or a phone visit in our cancer genetics clinic per standard of care. Patients randomized to the GIA arm will receive a personalized link based on their family history. At the completion of counseling, participants will be offered genetic testing. If they agree, they will be mailed a saliva kit via Invitae Genetics for panel based genetic testing via The Invitae Common Hereditary Cancers panel to analyze 47 genes associated with cancers of the breast, ovary, uterus, and gastrointestinal system, which includes the stomach, colon, rectum, small bowel, and pancreas.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 96
Est. completion date March 15, 2025
Est. primary completion date March 15, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - At high risk for having a genetic pathogenic variant as assessed by a GC or physician according to the NCCN guidelines - Provision of signed and dated informed consent form. - Stated willingness to comply with all study procedures and availability for the duration of the study. - Male or female, aged 18 and over. - Subjects must have a smartphone with access to cellular and/or internet service or a computer with internet service. - Subjects must have technological competency/proficiency to use their Smartphone and/or computer in conjunction with the communication aid GIA. Exclusion Criteria: - Cannot communicate in English or Spanish. - Subjects must not have completed panel-based cancer genetic testing in the past.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Genetic Information Assistant
Participants assigned will receive a link to Genetic Information Assistant for pre-test counseling.
Telegenetics with UVA genetic counselor
Participants assigned will have a pre-test counseling session via a telegentics visit with a genetic counselor.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Outcome

Type Measure Description Time frame Safety issue
Primary To assess feasibility of using a chatbot (GIA) for pre-test genetic counseling compared to standard of care GC dichotomous measurement of whether the randomized participant completes genetic testing within three months. 3 months
Secondary To test cancer knowledge following the pre-test genetic counseling with GIA versus GC National Center for Human Genome Research Knowledge scale taken at baseline and one month after genetic testing. 3 months
Secondary To assess differences of Comprehensive Score of Financial Toxicity scale To assess the difference in comprehensive score between one- and six-months of Comprehensive Score for Financial Toxicity (COST) survey. Scoring: 0 (Poor Financial well-being) to 48 (Better financial well-being) 6 months
Secondary To assess differences of SURE scale To assess the difference in comprehensive scores of the following surveys between one- and six-months of SURE scale. Scoring 0-4: Score <4 is a positive result for decisional conflict. 6 months
Secondary To assess differences of Decisional Conflict scale To assess the difference in comprehensive scores of the following surveys between one- and six-months Decisional Conflict Scale. Scoring: 0 (no decisional conflict) to 100 (extremely high decisional conflict) 6 months
Secondary To assess differences of Multi-dimensional Impact of Cancer Risk Assessment (MICRA) scale To assess the difference in comprehensive scores of the following surveys between one- and six-months Multi-dimensional Impact of Cancer Risk Assessment (MICRA) survey 6 months
See also
  Status Clinical Trial Phase
Completed NCT04746794 - Early Detection of GEnetic Risk (EDGE) N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Not yet recruiting NCT06441942 - Prospective Multicenter Registry of Gender, Diversity and Inclusion (GEDI) of Women With Acute Coronary Syndrome
Terminated NCT04119596 - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting NCT04141462 - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer N/A
Completed NCT02826330 - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting NCT05929976 - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting NCT04620278 - Genetic Investigation of Cancer Predisposition
Active, not recruiting NCT02373709 - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Completed NCT05975489 - Genetics in the Effect of Caffeine on Fat Oxidation N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Completed NCT04113239 - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation NCT04373525 - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed NCT03362099 - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) Phase 4
Recruiting NCT05857670 - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting NCT04774445 - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes N/A
Recruiting NCT05759143 - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing N/A
Active, not recruiting NCT04920513 - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting NCT04781205 - Genome Driven Primary Care Clinics - an RCT N/A